Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study.
about
The role of genetics in IBS.Genetic epidemiology of irritable bowel syndromeGenetic polymorphism in pathogenesis of irritable bowel syndromeFunctional GI disorders: from animal models to drug development.Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.Effect of selective CCK1 receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders.Current insights in to the pathophysiology of Irritable Bowel Syndrome.Association of CCK(1) Receptor Gene Polymorphisms and Irritable Bowel Syndrome in Korean.Review article: new receptor targets for medical therapy in irritable bowel syndromeMetabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome.Inclusion criteria for pharmacodynamic and clinical trials in chronic idiopathic constipation: pitfalls in using Rome III for functional constipationTreatment of irritable bowel syndrome: beyond fiber and antispasmodic agents.The role of experimental models in developing new treatments for irritable bowel syndrome.Anti-Gastrins Antiserum Combined with Lowered Dosage Cytotoxic Drugs to Inhibit the Growth of Human Gastric Cancer SGC7901 Cells in Nude Mice.Scintigraphic biomarkers for colonic dysmotility.Pharmacogenomics and functional gastrointestinal disorders.Psychopharmacological treatment and psychological interventions in irritable bowel syndrome.The relationship between gastric emptying, plasma cholecystokinin, and peptide YY in critically ill patients.Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations.Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease.Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity.Genetic and Non-genetic Factors Associated With Constipation in Cancer Patients Receiving Opioids.Structural basis of cholecystokinin receptor binding and regulation.Lower gastrointestinal functions.Updates on treatment of irritable bowel syndrome.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Genetic determination of irritable bowel syndrome.Current and novel therapeutic options for irritable bowel syndrome management.Investigational agents for the irritable bowel syndrome.Existing and emerging therapies for irritable bowel syndrome.Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.Review article: the role of gastrointestinal hormones in the treatment of delayed gastric emptying in critically ill patients.On the fiftieth anniversary. Postinfectious irritable bowel syndrome: mechanisms related to pathogens.Pain management in patients with inflammatory bowel disease: translational approaches from bench to bedside.New pharmacological treatment options for irritable bowel syndrome with constipation.Dexloxiglumide for the treatment of constipation predominant irritable bowel syndrome.Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.Changing face of irritable bowel syndrome.Susceptibility genes and functional gastrointestinal disorders.A study of candidate genotypes associated with dyspepsia in a U.S. community.
P2860
Q24600235-D69DBCB7-76EA-4A59-A893-4CD1E0D2B8A6Q26777392-39981E82-3E87-4451-9CAA-C36A374CB38FQ27008164-627CA52B-C16A-40A7-8305-BF98725645A9Q30433078-009E84F6-DD90-4858-8B7B-F356C1B53EE5Q30487910-666991B0-B467-44EF-9FDF-62ADDAF46061Q33466223-37F1E388-24EA-4D22-9F48-AFF8DD6144F1Q33875272-A810BCD1-7923-4A45-9274-6D6A4348FC9FQ33890473-A8129766-DF29-4AE6-B67F-AEB083977822Q33959307-155378DA-4DAB-49F8-B68D-F1EF93F31A00Q34323319-ED441FCD-8E54-4873-92D3-627FB9C7D6EDQ35018425-3EFAC9F1-C2C7-49ED-AC25-ADAF93EF76C1Q35018460-8663D6BF-D9C2-4F6A-AA0D-48BAD2278185Q35071310-B6916D83-7545-49C3-B1D5-278B1D5007A9Q35349177-997EB531-401B-44CC-A83F-DB3744EF680BQ35384517-8DEFC975-6824-45DB-85AA-781BE6FBFBB9Q36192802-96A10755-3C58-4D05-B53E-557072015F6AQ36203967-A7003F9E-CF8F-432C-B565-38EAE0925539Q36465450-1202F28F-18D0-4449-BC4B-89744898518FQ36487263-39B27201-50B2-4B4F-BE31-8D53BB84C603Q36583822-BD9F67A9-907D-4248-99C1-2A285A879106Q36728938-5BC8BF69-534C-4143-B90D-25CBA3F7E66DQ36751995-4E46FE88-9367-4F78-AC54-91EBCE094800Q36944147-6537C156-3951-4BE6-B4B3-A4FC64680A1CQ37134561-59B0599C-1674-432A-93EB-84F1CECF3CEBQ37156627-7AE194AD-FF0E-42CC-AA05-D96BDF192438Q37164063-1DFDF597-5456-46F6-A0FE-92BFA1535308Q37335246-082B0E2E-994E-4650-87CB-D8BA63B4C912Q37438547-C29CB669-BB80-44BD-A0F0-CD2B44E80852Q37788218-58ABCEED-DA1E-45D8-968B-63FF0D63E053Q37857849-0AEEF19B-C607-4133-B209-3440B64AE817Q38086870-C34FBFA6-D4B6-4BF4-8B0B-B0B0F93F037EQ38123557-16E27C60-595E-4D35-A7A8-55503D27A91AQ38179528-AAE985F8-EB9E-42A5-81C7-D08C75D0C8F4Q38248113-19027A61-9761-4A80-BC54-39443A02FF7FQ38628078-28A7C365-0338-4D38-8341-BAFDA0DAB023Q38824780-EA472324-406A-421B-A203-FC5EFF82E12DQ39348241-18EA1C7A-ACEE-4D95-8116-D5D489308B47Q42716570-9A203D7A-02BF-46C7-820D-B6735BC0A9B1Q46771580-BB6AA2BC-DA95-4B92-BBA8-846E290B9A3FQ46932419-70FFB7D9-F175-4A4B-A629-586EBDEE8A9B
P2860
Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Effect of CCK-1 antagonist, de ...... mic and pharmacogenomic study.
@ast
Effect of CCK-1 antagonist, de ...... mic and pharmacogenomic study.
@en
Effect of CCK-1 antagonist, de ...... mic and pharmacogenomic study.
@nl
type
label
Effect of CCK-1 antagonist, de ...... mic and pharmacogenomic study.
@ast
Effect of CCK-1 antagonist, de ...... mic and pharmacogenomic study.
@en
Effect of CCK-1 antagonist, de ...... mic and pharmacogenomic study.
@nl
prefLabel
Effect of CCK-1 antagonist, de ...... mic and pharmacogenomic study.
@ast
Effect of CCK-1 antagonist, de ...... mic and pharmacogenomic study.
@en
Effect of CCK-1 antagonist, de ...... mic and pharmacogenomic study.
@nl
P2093
P2860
P1476
Effect of CCK-1 antagonist, de ...... mic and pharmacogenomic study.
@en
P2093
Christopher E Camilleri
Duane Burton
Filippo Cremonini
George Thomforde
Paula Carlson
Raul Urrutia
Sanna McKinzie
P2860
P304
P356
10.1111/J.1572-0241.2005.41081.X
P407
P577
2005-03-01T00:00:00Z